Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will ...

The days of fishing shirtless or in a plain cotton t-shirt are over – not only because we’re much more aware of the potential for sun damage, but also because we know that the best fishing shirts can ...

The latest price target for Eli Lilly (NYSE:LLY) was reported by UBS on May 2, 2025. The analyst firm set a price target for $1050.00 expecting LLY to rise to within 12 months (a possible 42.32% ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. The Tempo system brings ...

Eli Lilly, the manufacturer of Zepbound, made Zepbound available on its online pharmacy, LillyDirect, in August 2024. The medication is available as a single-dose vial or an auto-injector pen.

treatment plan for patients with breast cancer is the first digital health product to emerge from a newly-announced partnership between digital health specialist Sidekick and pharma group Eli ...